Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care,...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
NCT06783140 · Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, and more
NCT07321015 · Platinum-sensitive, TNBC, Triple Negative Breast Cancer, and more
NCT06534424 · BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Memorial Sloan Kettering Cancer Center
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions